Publications by authors named "Nathan Denlinger"

Claim this Profile
I
Isolated oral CD30/CD4 CAR T cell lymphoma in long-term remission after radiotherapy.
Evandro Bezerra, Ludmila Lupu, Marcos de Lima, Lena Pfaller, Alison Neal, Nathan Denlinger

Mol Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphoma.
John Sharp, Qiuhong Zhao, Timothy J Voorhees, David A Bond, Yazeed Sawalha, Nathan Denlinger

Br J Haematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies.
Elvira Umyarova, Charles Pei, William Pellegrino, Qiuhong Zhao, Nidhi Sharma, Nathan Denlinger

J Hematol Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis.
Amneet Bajwa, Qiuhong Zhao, Marcus Geer, Chenyu Lin, James Westholder, Nathan Denlinger

Blood Adv· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program.
Timothy J Voorhees, Evandro Bezerra, Nathan Denlinger, Samantha Jaglowski, Marcos de Lima

Clin Lymphoma Myeloma Leuk· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stem-like CD8 T cells in cancer.
Chelsea Steiner, Nathan Denlinger, Xiaopei Huang, Yiping Yang

Front Immunol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma.
Nathan Denlinger, No-Joon Song, Xiaoli Zhang, Hyeongseon Jeon, Chelsea Peterson

Blood Adv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models.
Wing Keung Chan, Jessica Williams, Kinnari Sorathia, Betsy Pray, Kaled Abusaleh, Nathan Denlinger

Exp Hematol Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.
Joanna Zurko, Imran Nizamuddin, Narendranath Epperla, Kevin David, Jonathon B Cohen, Nathan Denlinger

Blood Adv· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy.
Joseph H Azar, John P Evans, Madison H Sikorski, Karthik B Chakravarthy, Selah McKenney, Nathan Denlinger

JCI Insight· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
Joanna Zurko, Jeremy Ramdial, Mazyar Shadman, Sairah Ahmed, Aniko Szabo, Nathan Denlinger

Haematologica· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent Advances and Challenges in Cancer Immunotherapy.
Chelsea Peterson, Nathan Denlinger, Yiping Yang

Cancers (Basel)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma.
Amneet Bajwa, Ying Huang, Rui Li, Nathan Denlinger, Jonathan Brammer

Leuk Lymphoma· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma.
Audrey M Sigmund, Nathan Denlinger, Ying Huang, David Bond, Timothy Voorhees

Transplant Cell Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML.
H Moses Murdock, Haesook T Kim, Nathan Denlinger, Pankit Vachhani, Bryan Hambley

Blood· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR T-cell therapy for B-cell lymphoma.
Nathan Denlinger, David Bond, Samantha Jaglowski

Curr Probl Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma.
Jonathan E Brammer, Zachary Braunstein, Aashish Katapadi, Kyle Porter, Michael Biersmith, Nathan Denlinger

J Immunother Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis.
Adam S Kittai, Ying Huang, Max Gordon, Nathan Denlinger, Agrima Mian

Transplant Cell Ther· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma.
Bethany Mundy-Bosse, Nathan Denlinger, Eric McLaughlin, Nitin Chakravarti, Susan Hwang

Blood Adv· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive performance of early warning scores in acute leukemia patients receiving induction chemotherapy.
John L Vaughn, David Kline, Nathan M Denlinger, Leslie A Andritsos, Matthew C Exline

Leuk Lymphoma· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.
Nathan M Denlinger, Narendranath Epperla, Basem M William

Cancer Manag Res· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toll-like receptor 3 is critical for coxsackievirus B4-induced type 1 diabetes in female NOD mice.
Kelly D McCall, Jean R Thuma, Maria C Courreges, Fabian Benencia, Calvin B L James, Nathan Denlinger

Endocrinology· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis